Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial

Table 6

Incidence of AEs in ≥5% of patients by treatment.

AE, n (%)	Fentanyl matrix (N = 52)	Gabapentin (N = 56)	Total (N = 108)
Dizziness	16 (30.8%)	25 (44.6%)	41 (38.0%)
Somnolence	15 (28.8%)	21 (37.5%)	36 (33.3%)
Nausea	19 (36.5%)	4 (7.1%)	23 (21.3%)
Constipation	8 (15.4%)	10 (17.9%)	18 (16.7%)
Vomiting	11 (21.2%)	2 (3.6%)	13 (12.0%)
Asthenia	7 (13.5%)	8 (14.3%)	15 (13.9%)
Headache	3 (5.8%)	4 (7.1%)	7 (6.5%)

AE: adverse event.